GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Control Bionics Ltd (ASX:CBL) » Definitions » 14-Day RSI

Control Bionics (ASX:CBL) 14-Day RSI : 45.27 (As of Mar. 29, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Control Bionics 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2025-03-29), Control Bionics's 14-Day RSI is 45.27.

The industry rank for Control Bionics's 14-Day RSI or its related term are showing as below:

ASX:CBL's 14-Day RSI is ranked better than
54.66% of 891 companies
in the Medical Devices & Instruments industry
Industry Median: 46.56 vs ASX:CBL: 45.27

Competitive Comparison of Control Bionics's 14-Day RSI

For the Medical Devices subindustry, Control Bionics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Control Bionics's 14-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Control Bionics's 14-Day RSI falls into.


;
;

Control Bionics  (ASX:CBL) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Control Bionics  (ASX:CBL) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Control Bionics 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Control Bionics's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Control Bionics Business Description

Traded in Other Exchanges
N/A
Address
11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically it derives a majority of revenue from North America and has its presence in Australia as well.